The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 ...
Saqib Islam, chief executive Officer of newly launched Beeline Medicines. The pace of private financing in biopharma steps up ...
Beeline Medicines launches with $300 million from Bain Capital and five drug programs from Bristol Myers Squibb, including a ...
Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...
Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases – – Lead program afimetoran, a potential best-in-disease ...
Pharma Finance Roundup: Platform Innovation Drives Biotech Investment Across Oncology and Immunology
Launch financing of $300M enables Beeline to operationalize an in-licensed immunology portfolio, with afimetoran (TLR7/8) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results